Abstract
Pfizer keeps making a positive difference in the world for the benefit of countless patients, according to the 2021 Pfizer Annual Report. The outbreak of COVID-19 has sent Pfizer's results skyrocketing, while Pfizer has also used the data to satisfy its stakeholders and the general public. This essay conducts an objective analysis of Pfizer's annual financial statements for 2019-2021, including balance sheet analysis, income statement analysis, cash flow statement analysis, financial ratio analysis, and Du-pont analysis. The research demonstrates an overall upward trend in Pfizer's revenues. It is primarily motivated by sales growth across the Pfizer portfolio. The company's net income grew because of increased revenue and the implementation of cost-cutting measures. Pfizer kept a solid financial position and a healthy cash balance, allowing it to invest in R&D, make strategic acquisitions, and return value to shareholders through dividends and share repurchases. Ultimately, the financial report demonstrates Pfizer's dedication to driving long-term growth and creating value for its stakeholders.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
